ArticleFrontiers in oncology2022

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.

Ying Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.